Evidence mapPaperPMID 37568493Full record

ReviewJournal of clinical medicine2023

Hypertensive Heart Failure.

Filippos Triposkiadis, Pantelis Sarafidis, Alexandros Briasoulis, Dimitrios E Magouliotis, Thanos Athanasiou, John Skoularigis, Andrew Xanthopoulos

Open access · goldAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Low and High Pressor Doses of Ang II Lead to Two Distinct Phenotypes of Hypertensive Heart Disease in Mice.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026
    Article
  5. Article
  6. Review
  7. One Syndrome, Many Faces: A Unified Perspective on Heart Failure Phenotypes.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Hypertension and Heart Failure: From Pathophysiology to Treatment.International journal of molecular sciences · 2024
    Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 3 countries.

Filippos TriposkiadisSchool of Medicine, European University Cyprus, 2404 Nicosia, Cyprus.ORCID 0000-0001-6433-4016
Pantelis SarafidisDepartment of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.ORCID 0000-0002-9174-4018
Alexandros BriasoulisDepartment of Therapeutics, Heart Failure and Cardio-Oncology Clinic, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-5740-9670
Dimitrios E MagouliotisUnit of Quality Improvement, Department of Cardiothoracic Surgery, University of Thessaly, 41110 Larissa, Greece.
Thanos AthanasiouDepartment of Surgery and Cancer, Imperial College London, St Mary's Hospital, London W2 1NY, UK.
John SkoularigisDepartment of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece.ORCID 0000-0001-7159-2478
Andrew XanthopoulosDepartment of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece.ORCID 0000-0002-9439-3946
University Hospital of Larissa · GRAristotle University of Thessaloniki · GREuropean University Cyprus · CYNational and Kapodistrian University of Athens · GRSt Mary's Hospital · GBUniversity of Thessaly · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite overwhelming epidemiological evidence, the contribution of hypertension (HTN) to heart failure (HF) development has been undermined in current clinical practice. This is because approximately half of HF patients have been labeled as suffering from HF with preserved left ventricular (LV) ejection fraction (EF) (HFpEF), with HTN, obesity, and diabetes mellitus (DM) being considered virtually equally responsible for its development. However, this suggestion is obviously inaccurate, since HTN is by far the most frequent and devastating morbidity present in HFpEF. Further, HF development in obesity or DM is rare in the absence of HTN or coronary artery disease (CAD), whereas HTN often causes HF per se. Finally, unlike HTN, for most major comorbidities present in HFpEF, including anemia, chronic kidney disease, pulmonary disease, DM, atrial fibrillation, sleep apnea, and depression, it is unknown whether they precede HF or result from it. The purpose of this paper is to provide a contemporary overview on hypertensive HF, with a special emphasis on its inflammatory nature and association with autonomic nervous system (ANS) imbalance, since both are of pathophysiologic and therapeutic interest.

Indexed as

autonomic imbalanceejection fractionheart failurehypertensionsympathetic nervous system

Identifiers

PMID37568493
PMCPMC10419453
OpenAlexW4385489928

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.